Cargando…

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges

Detalles Bibliográficos
Autores principales:	Mistry, Pramod, Balwani, Manisha, Barbouth, Deborah, Burrow, T. Andrew, Ginns, Edward I., Goker-Alpan, Ozlem, Grabowski, Gregory A., Kartha, Reena V., Kishnani, Priya S., Lau, Heather, Lee, Chung U., Lopez, Grisel, Maegawa, Gustavo, Packman, Seymour, Prada, Carlos, Rosenbloom, Barry, Lal, Tamanna Roshan, Schiffmann, Rapheal, Weinreb, Neal, Sidransky, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211677/ https://www.ncbi.nlm.nih.gov/pubmed/32471800 http://dx.doi.org/10.1016/j.ymgme.2020.05.002

Ejemplares similares

COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic
por: Ryan, Emory, et al.
Publicado: (2021)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

The Spectrum of Neurological Manifestations Associated with Gaucher Disease
por: Roshan Lal, Tamanna, et al.
Publicado: (2017)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown
por: Ginns, Edward I., et al.
Publicado: (2021)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes
por: Orenstein, Marissa, et al.
Publicado: (2014)

Modeling potential interactions between oral Gaucher disease treatment and investigational COVID-19 therapies
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2021)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Efferocytosis is impaired in Gaucher macrophages
por: Aflaki, Elma, et al.
Publicado: (2017)

Bilateral femoral osteolytic lesions in a patient with type 3 Gaucher disease
por: Teefe, Enock, et al.
Publicado: (2015)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases
por: Ivanova, Margarita M., et al.
Publicado: (2019)

Rapid-Onset Dystonia and Parkinsonism in a Patient With Gaucher Disease
por: Hertz, Ellen, et al.
Publicado: (2023)

The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease
por: Stiles, Ashlee R., et al.
Publicado: (2021)

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
por: Sims, KB, et al.
Publicado: (2008)

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
por: Ivanova, Margarita, et al.
Publicado: (2021)

Patients with Gaucher disease display systemic oxidative stress dependent on therapy status
por: Kartha, Reena V., et al.
Publicado: (2020)

Biofabrication of an in-vitro bone model for Gaucher disease
por: Banerjee, Dishary, et al.
Publicado: (2023)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease
por: Limgala, Renuka Pudi, et al.
Publicado: (2016)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Longitudinal evaluation of olfactory function in individuals with Gaucher disease and GBA1 mutation carriers with and without Parkinson's disease
por: Lopez, Grisel J., et al.
Publicado: (2022)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2022)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
por: Mistry, Pramod K., et al.
Publicado: (2017)

Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages
por: Aflaki, Elma, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4jjjh31rcaggsrm68jgb6qbk40